GetTopicDetailResponse(id=f91412114508, topicName=免疫治療耐藥, introduction=, content=經(jīng)典型霍奇金淋巴瘤 免疫治療耐藥, image=null, comments=0, allHits=435, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Nov 09 23:45:07 CST 2024, time=2024-11-09, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=475726, tagList=[TagDto(tagId=475726, tagName=免疫治療耐藥)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2236139, encodeId=7f092236139ba, content=<a href='/topic/show?id=094be82196d' target=_blank style='color:#2F92EE;'>#經(jīng)典型霍奇金淋巴瘤#</a> <a href='/topic/show?id=f91412114508' target=_blank style='color:#2F92EE;'>#免疫治療耐藥#</a>, objectTitle=【Blood】地西他濱、西達(dá)本胺、卡瑞利珠單抗治療經(jīng)典型霍奇金淋巴瘤安全有效, objectType=article, longId=850532, objectId=a68185053273, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241108/1731046030949_8538692.jpg, objectUrl=/article/show_article.do?id=a68185053273, replyNumber=0, likeNumber=39, createdTime=2024-11-09, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a68185053273, moduleTitle=【Blood】地西他濱、西達(dá)本胺、卡瑞利珠單抗治療經(jīng)典型霍奇金淋巴瘤安全有效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a68185053273)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-11-09發(fā)表于上海
